Kadmon (KDMN) Rating Increased to Buy at Zacks Investment Research

Kadmon (NYSE:KDMN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 12.24% from the company’s previous close.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

Other analysts have also issued reports about the stock. HC Wainwright set a $25.00 target price on shares of Kadmon and gave the company a “buy” rating in a research note on Monday, August 13th. ValuEngine upgraded shares of Kadmon from a “hold” rating to a “buy” rating in a report on Wednesday, November 7th. Finally, WBB Securities upgraded shares of Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price target on the stock in a report on Wednesday, October 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $11.13.

KDMN stock opened at $2.45 on Thursday. Kadmon has a 12 month low of $1.88 and a 12 month high of $5.86. The company has a market cap of $277.10 million, a P/E ratio of -1.73 and a beta of 3.57. The company has a quick ratio of 3.08, a current ratio of 6.64 and a debt-to-equity ratio of 0.32.

A number of hedge funds have recently bought and sold shares of KDMN. Vivo Capital LLC grew its position in Kadmon by 213.6% in the second quarter. Vivo Capital LLC now owns 10,454,545 shares of the company’s stock worth $68,919,000 after acquiring an additional 7,121,212 shares in the last quarter. BlackRock Inc. grew its position in Kadmon by 209.3% in the second quarter. BlackRock Inc. now owns 4,763,436 shares of the company’s stock worth $19,005,000 after acquiring an additional 3,223,211 shares in the last quarter. Acuta Capital Partners LLC grew its position in Kadmon by 52.3% in the second quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock worth $36,149,000 after acquiring an additional 3,110,014 shares in the last quarter. VHCP Management III LLC bought a new stake in shares of Kadmon during the 3rd quarter worth $7,978,000. Finally, VHCP Management II LLC bought a new stake in shares of Kadmon during the 2nd quarter worth $5,632,000. 69.68% of the stock is owned by institutional investors.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Further Reading: Fundamental Analysis

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply